Brief: Oryzon Presents Data For Iadademstat Combinations In AML Patients

ORYZON Genomics SA

09/12/2025 07:37

Dec 9 (Reuters) - Oryzon Genomics SA  ORY.MC :
    * PRESENTS UPDATED DATA ON IADADEMSTAT
    * 100% GLOBAL RESPONSE RATE IN AML STUDY WITH AZACITIDINE
AND
VENETOCLAX
    * IADADEMSTAT TREATMENT SAFE AND WELL TOLERATED
    * 80% COMPLETE RESPONSES AND 90% COMPOSITE COMPLETE RESPONSE
RATE;
MEDIAN OVERALL SURVIVAL NOT REACHED AFTER 9 MONTHS AND GOOD
TOLERABILITY

Source text:  ID:nCNMKqtgPF 
Further company coverage:  ORY.MC 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))